Clinical Trials Browser

Amifostine × Plasma cell × Clear all

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00217438 2015-08-21

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Phase 3 Completed

130 enrolled 6 charts

Plasma cell

Multiple Myeloma

NCT00003425 2013-04-26

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Phase 1/2 Completed

25 enrolled

BreastCNSGynecologicLymphoidOther hematologic neoplasmPlasma cellSarcoma

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma